RAPID CTA, a three-dimensional (3D) imaging solution for computed tomography angiography (CTA) from iSchemaView, has received final clearance from the U.S. Food and Drug Administration (FDA). This new software system expand’s the company’s neuroimaging portfolio of products designed to provide physicians with fast, fully-automated, elegant, and easy-to-interpret imaging to facilitates clinical decisions relating to cerebrovascular disease. Other iSchemaView products include RAPID CTP and RAPID MRI.
RAPID CTA automatically provides clear, easy-to-interpret CTA maps which include a colored overlay to identify brain regions with reduced blood vessel density. The severity of reduction can be readily visualized by a simple, four-color-coded scale. Additionally, a 3D reconstruction of the vasculature allows physicians to rotate the image for optimal viewing of the vessels from multiple angles. The new, automated RAPID CTA tool is designed to help emergency physicians and radiologists to quickly identify potential candidates for treatment, and for experts at
The system also includes remote viewing functionality, according to the Redwood City, CA-headquartered company. Image maps can be displayed for review on any desktop or notebook computer or other mobile device. Remote viewing can facilitate clinical decision making, patient triage, collaboration between community hospitals and specialists, and appropriate patient transfers to specialty centers.Back To Top
iSchemaView’s RAPID CTA 3D software cleared by FDA. Appl Radiol.